P
Paolo de Fabritiis
Researcher at University of Rome Tor Vergata
Publications - 234
Citations - 3483
Paolo de Fabritiis is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Myeloid leukemia & Multiple myeloma. The author has an hindex of 27, co-authored 220 publications receiving 2917 citations. Previous affiliations of Paolo de Fabritiis include University of Turin & Hammersmith Hospital.
Papers
More filters
Journal ArticleDOI
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Sergio Amadori,Stefan Suciu,Dominik Selleslag,Franco Aversa,Gianluca Gaidano,Maurizio Musso,Luciana Annino,Adriano Venditti,Maria Teresa Voso,Carla Mazzone,Domenico Magro,Paolo de Fabritiis,Petra Muus,Giuliana Alimena,Marco Mancini,Anne Hagemeijer,Francesca Paoloni,Marco Vignetti,Paola Fazi,Liv Meert,Safaa M. Ramadan,Roel Willemze,Theo de Witte,Frédéric Baron +23 more
TL;DR: First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy.
Journal ArticleDOI
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.
Wilma Barcellini,Bruno Fattizzo,Anna Zaninoni,Tommaso Radice,Ilaria Nichele,Eros Di Bona,Monia Lunghi,C Tassinari,Fiorella Alfinito,Antonella Ferrari,Anna Paola Leporace,Pasquale Niscola,Monica Carpenedo,Carla Boschetti,Nicoletta Revelli,Maria Antonietta Villa,Dario Consonni,Laura Scaramucci,Paolo de Fabritiis,Giuseppe Tagariello,Gianluca Gaidano,Francesco Rodeghiero,Agostino Cortelezzi,Alberto Zanella +23 more
TL;DR: Predictors of a fatal outcome were severe infections, particularly in splenectomized cases, acute renal failure, Evans syndrome, and multitreatment (4 or more lines).
Journal ArticleDOI
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia
Maria Ilaria Del Principe,Giovanni Del Poeta,Francesco Buccisano,Luca Maurillo,Adriano Venditti,Antonella Zucchetto,Rita Marini,Pasquale Niscola,Maria Antonietta Irno Consalvo,Carla Mazzone,Licia Ottaviani,Paola Panetta,Antonio Bruno,Riccardo Bomben,G Suppo,Massimo Degan,Valter Gattei,Paolo de Fabritiis,Maria Cantonetti,Francesco Lo Coco,Domenico Del Principe,Sergio Amadori +21 more
TL;DR: ZAP-70 protein determined by flow cytometry improves the prognostic significance of cytogenetics and appears to be a better predictor of outcomes than IgV(H) gene mutational status.
Journal ArticleDOI
Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia
Luca Maurillo,Francesco Buccisano,Maria Ilaria Del Principe,Giovanni Del Poeta,Alessandra Spagnoli,Paola Panetta,Emanuele Ammatuna,Benedetta Neri,Licia Ottaviani,Chiara Sarlo,Daniela Venditti,Micol Quaresima,Raffaella Cerretti,Manuela Rizzo,Paolo de Fabritiis,Francesco Lo Coco,William Arcese,Sergio Amadori,Adriano Venditti +18 more
TL;DR: A threshold of 3.5 x 10(-4) residual leukemia cells postconsolidation is critical for predicting disease outcome and MRD-negative patients have a good outcome regardless of the type of transplant they receive, while in the MRd-positive group, AuSCT does not improve prognosis and SCT represents the primary option.
Journal ArticleDOI
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
Adriano Venditti,Alfonso Piciocchi,Anna Candoni,Lorella Melillo,Valeria Calafiore,Roberto Cairoli,Paolo de Fabritiis,Gabriella Storti,Prassede Salutari,Francesco Lanza,Giovanni Martinelli,Mario Luppi,Patrizio Mazza,Maria Paola Martelli,Antonio Cuneo,Francesco Albano,Francesco Fabbiano,Agostino Tafuri,Anna Chierichini,Alessia Tieghi,Nicola Stefano Fracchiolla,Debora Capelli,Robin Foà,Caterina Alati,Edoardo La Sala,Paola Fazi,Marco Vignetti,Luca Maurillo,Francesco Buccisano,Maria Ilaria Del Principe,Maria Irno-Consalvo,Tiziana Ottone,Serena Lavorgna,Maria Teresa Voso,Francesco Lo-Coco,William Arcese,Sergio Amadori +36 more
TL;DR: A trial in which post-remission therapy of young patients with de novo AML was decided combining cytogenetics/genetics and post-consolidation levels of minimal residual disease, AuSCT may still have a role in FR and IR MRD-negative categories and ASCT prolongs OS and DFS to equal those of the FR category.